Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Uncertain Future For Otelixizumab In Type 1 Diabetes After Phase III Failure

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

GlaxoSmithKline and Tolerx announced March 11 that their humanized anti-CD3 monoclonal antibody, otelixizumab failed to meet the primary endpoint in the Phase III DEFEND-1 trial for type 1 diabetes, and they were halting recruitment and dosing in another Phase III trial, DEFEND-2, while they review the DEFEND-1 results.
Advertisement

Related Content

GSK Announces Share Buyback Program As Pretax Profits Fall By 52% In 2010
GSK Signs Deal For Tolerx Anti-CD3 Antibody For Type 1 Diabetes
GSK Signs Deal For Tolerx Anti-CD3 Antibody For Type 1 Diabetes
Lilly Sweet On MacroGenics’ Novel Diabetes Drug Teplizumab

Topics

Advertisement
UsernamePublicRestriction

Register

PS004701

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel